8-K: BioCardia's CardiAMP-HF Trial Shows Positive Two-Year Outcomes in Heart Failure Patients

BioCardia announces positive two-year results from its Phase 3 CardiAMP-HF trial, demonstrating increased survival, decreased cardiac events, and improved quality of life in ischemic heart failure patients treated with CardiAMP cell therapy.

Summary

• BioCardia, Inc. announced two-year outcomes from its Phase 3 CardiAMP-HF study, a double-blind, randomized, placebo-controlled trial.
• The study evaluated CardiAMP autologous minimally invasive cell therapy for ischemic heart failure patients with reduced ejection fraction (HFrEF).
• The trial involved 115 patients enrolled at 18 centers in the United States and Canada, all maintained on heart failure medication.
• Patients receiving CardiAMP Cell Therapy showed decreased mortality and MACCE (major adverse cardiac and cerebrovascular events), with improved quality of life, compared to those on medication alone.
• In patients with elevated NTproBNP biomarkers (50% of enrolled patients), there was a 13% reduction in heart death equivalents and a 2% reduction in non-fatal MACCE.
• This subgroup also experienced a clinically meaningful 10.5-point improvement in quality-of-life score and a 13.9-meter improvement in Six Minute Walk Distance.
• Across all treated patients, there was a 3.6% reduction in heart death equivalents and an 8.7% reduction in non-fatal MACCE.
• The therapy also showed a clinically meaningful 5.5-point improvement in quality of life score for all treated patients.
• The results suggest that a single dose of CardiAMP therapy offers durable benefits for at least two years.
• BioCardia plans to share the data with the U.S. FDA and Japan PMDA to align on regulatory pathways.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial results, highlighting improvements in survival, cardiac events, and quality of life. The FDA Breakthrough designation further supports a positive outlook.

Positives

• CardiAMP Cell Therapy shows increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE).
• The therapy improves the quality of life for heart failure patients.
• The benefits appear to be greater in patients with elevated NTproBNP biomarkers.
• The therapy has durable benefits at two years, suggesting lasting effects.
• CardiAMP Cell Therapy has been granted FDA Breakthrough designation, indicating significant potential to improve upon current therapies.
• The therapy has the potential to reduce healthcare costs associated with heart failure.

Negatives

• The primary composite efficacy endpoint did not reach statistical significance study-wide.
• The study only included 115 patients, which may limit the generalizability of the results.

Risks

• The forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• Regulatory approvals are not guaranteed.
• The market opportunity for CardiAMP therapy depends on achieving regulatory approval and demonstrating cost-effectiveness.

Future Outlook

BioCardia looks forward to sharing the CardiAMP-HF two-year data with both the U.S. FDA and Japan PMDA soon to align on the pathways that could make it available for physicians and their patients as soon as possible.

Management Comments

• Dr. Raval stated that CardiAMP therapy has the potential to safely and significantly improve survival and quality of life for heart failure patients in distress.
• Dr. Pepine noted that the results were durable at two years, suggesting the therapy may have lasting benefits.
• Peter Altman, PhD, stated that the patient benefits help to clinically validate the therapy's observed mechanism of action.

Industry Context

The clinical trial was conducted because there remains a large group of heart failure patients today who are insufficiently responsive to optimized heart failure medication, suggesting a need for new therapies like CardiAMP.

Comparison to Industry Standards

• The document does not provide specific comparisons to other companies or projects.
• However, it highlights that CardiAMP Cell Therapy incorporates three proprietary elements not previously utilized in cardiac cell therapy: 1) a pre-procedural cell analysis to identify likely responders, 2) a high target dosage of cells, and 3) a minimally-invasive system for cell therapy delivery to the damaged area of the heart that has been shown to be safer and promote greater cell retention than other intramyocardial delivery systems.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and potential regulatory approvals.
• Patients with ischemic heart failure may have a new treatment option with improved outcomes.
• The healthcare system may benefit from reduced costs associated with heart failure care.

Next Steps

• BioCardia plans to share the CardiAMP-HF two-year data with the U.S. FDA and Japan PMDA.
• The company aims to align on regulatory pathways to make the therapy available for physicians and patients.

Key Dates

Keywords

CardiAMP, heart failure, cell therapy, ischemic heart failure, HFrEF, clinical trial, CardiAMP-HF, BioCardia, NTproBNP, MACCE